Literature DB >> 11231027

Phenotypic variation in a large Japanese family with Miyoshi myopathy with nonsense mutation in exon 19 of dysferlin gene.

M Nakagawa1, T Matsuzaki, M Suehara, N Kanzato, H Takashima, I Higuchi, T Matsumura, K Goto, K Arahata, M Osame.   

Abstract

Miyoshi myopathy, an autosomal recessive muscular dystrophy involving distal muscles, is caused by dysferlin mutations. We present clinical and genetic studies of two men and six women, aged 25-83 years, from a Japanese family with consanguineous marriages. Onset was between ages 17 and 59 years. Six of the patients had muscle involvement typical of Miyoshi myopathy, one initially had severe proximal muscle involvement, and one had scapuloperoneal-type muscle involvement. Three patients showed steppage gait. Genetic linkage analysis identified a maximum lod score of 3.34 (θ=0.00) at marker D2S292 in 2p13. Analysis of dysferlin revealed the mutation G2090T (Glu573Stop) in exon 19 in all affected patients. This is the largest Japanese family with Miyoshi myopathy showing intrafamilial phenotypic variation and sharing a common mutation in dysferlin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231027     DOI: 10.1016/s0022-510x(00)00484-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice.

Authors:  Christine A Kostek; Janice A Dominov; Jeffrey Boone Miller
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

2.  Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption.

Authors:  Alexis R Demonbreun; Madison V Allen; James L Warner; David Y Barefield; Swathi Krishnan; Kaitlin E Swanson; Judy U Earley; Elizabeth M McNally
Journal:  Am J Pathol       Date:  2016-04-09       Impact factor: 4.307

3.  Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia.

Authors:  Norah Alharbi; Rawan Matar; Edward Cupler; Hindi Al-Hindi; Hatem Murad; Iftteah Alhomud; Dorota Monies; Ali Alshehri; Mossaed Alyahya; Brian Meyer; Saeed Bohlega
Journal:  Front Neurosci       Date:  2022-02-22       Impact factor: 4.677

4.  Heterogeneous characteristics of Korean patients with dysferlinopathy.

Authors:  Hyung Jun Park; Ji-Man Hong; Gyoung Im Suh; Ha Young Shin; Seung Min Kim; Il Nam Sunwoo; Bum Chun Suh; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

5.  Twenty-Year Clinical Progression of Dysferlinopathy in Patients from Dagestan.

Authors:  Zoya R Umakhanova; Sergei N Bardakov; Mikhail O Mavlikeev; Olga N Chernova; Raisat M Magomedova; Patimat G Akhmedova; Ivan A Yakovlev; Gimat D Dalgatov; Valerii P Fedotov; Artur A Isaev; Roman V Deev
Journal:  Front Neurol       Date:  2017-03-08       Impact factor: 4.003

Review 6.  Functions of Vertebrate Ferlins.

Authors:  Anna V Bulankina; Sven Thoms
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

7.  The inflammatory pathology of dysferlinopathy is distinct from calpainopathy, Becker muscular dystrophy, and inflammatory myopathies.

Authors:  Nicole Becker; Steven A Moore; Karra A Jones
Journal:  Acta Neuropathol Commun       Date:  2022-02-08       Impact factor: 7.801

8.  Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects.

Authors:  Jens A Petersen; Thierry Kuntzer; Dirk Fischer; Maja von der Hagen; Angela Huebner; Veronika Kana; Johannes A Lobrinus; Wolfram Kress; Elisabeth J Rushing; Michael Sinnreich; Hans H Jung
Journal:  BMC Neurol       Date:  2015-10-06       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.